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Abstract
Background: Recently, a novel variant of ER-a, ER-a36 was identified and cloned. ER-a36 lacks intrinsic transcription activity
and mainly mediates nongenomic estrogen signaling. Here, we studied the role of nongenomic estrogen signaling
pathways mediated by ER-a36 in tamoxifen resistance and agonist action.
Methodology: The cellular localization of ER-a36 was examined by immunofluorescence in MCF-7 cells and Hec1A cells.
MCF-7 breast cancer cells, MCF-7 cells expressing recombinant ER-a36 (MCF-7/ER36), Hec1A endometrial cancer cells and
Hec1A cells with siRNA knockdown of ER-a36 (Hec1A/RNAiER36) were treated with 17b-estradial (E2) and tamoxifen (TAM)
in the absence and presence of kinase inhibitor U0126 and LY294002. We examined phosphorylation of signaling molecules
and the expression of c-Myc by immunoblotting, and tumor cell growth by MTT assay.
Conclusions: ER variant ER-a36 enhances TAM agonist activity through activation of the membrane-initiated signaling
pathways in endometrial cancer, and that ER-a36 is involved in de novo and acquired TAM resistance in breast cancer.
Citation: Lin S-L, Yan L-Y, Zhang X-T, Yuan J, Li M, et al. (2010) ER-a36, a Variant of ER-a, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the
MAPK/ERK and PI3K/Akt Pathways. PLoS ONE 5(2): e9013. doi:10.1371/journal.pone.0009013
Editor: Syed A. Aziz, Health Canada, Canada
Received December 11, 2009; Accepted January 13, 2010; Published February 2, 2010
Copyright:  2010 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by National Basic Research Program of China (2006CB504004, 2006CB944005). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jie.qiao@263.net (JQ); zywang@creighton.edu (Z-YW); sunqy@ioz.ac.cn (Q-YS)
Introduction
Tamoxifen is a selective estrogen receptor modulator (SERM)
with mixed agonist/antagonist activities that has been used widely
as an effective treatment of all stages of estrogen receptor (ER)-
positive breast cancer [1]. Tamoxifen suppresses the recurrence of
breast cancer and reduces the incidence of contralateral breast
cancer by 49% [2]. Tamoxifen has also been used as a
chemopreventive agent in women who have high risk for breast
cancer [3]. It is believed that tamoxifen acts as an antagonist by
competing with estrogens for the ligand binding domain of ER,
thereby inhibiting ER-mediated mitogenic estrogen signaling [4].
However, the major obstacle to tamoxifen usage is tamoxifen
resistance, which occurs de novo or can be acquired after its use [5].
In addition, tamoxifen usage increases the incidence of endome-
trial cancer in postmenopausal women with long-term treatment
[6]. The molecular mechanisms underlying both de novo and
acquired tamoxifen resistance and its agonist action in endometrial
tissue are poorly understood.
ER belongs to the steroid hormone family of the nuclear
receptor superfamily. It is prevailingly considered that ER acts as a
transcription factor that is mainly localized in the cell nucleus [7].
However, accumulating evidence has demonstrated that ER also
exists on the plasma membrane and participates in rapid estrogen
signaling. It has been reported that ER is modified by
posttranslational palmitoylation in the ligand-binding domain that
may contribute to its membrane localization [8]. Association of
ER and caveolin-1 also was shown to facilitate ER localization on
the plasma membrane [9]. Caveolin-1 is a structural protein of
caveolae and serves as a scaffold protein to recruit signaling
molecules such as growth factor receptors, G proteins, Src family
tyrosine kinases and the PI3K [10]. It was postulated that estrogen
may rapidly activate different signaling pathways, including
MAPK/ERK, phospholipase C, PI3K/Akt and G protein-
coupled receptor-activated pathways in the caveolae [11].
Recently, we identified and cloned a novel variant of ER-a with
a molecular weight of 36 kDa that was named as ER-a36 [12].
The original 66 kDa ER-a was named ER-a66 [13]. ER-a36
transcript is initiated from a promoter located in the first intron of
the ER-a66 gene and is generated from two alternative splicing
events. ER-a36 protein thus lacks ligand-dependent and -
independent transactivation domain (AF-1 and AF-2), but it
retains DNA- binding domain and partial dimerization domain
and ligand-binding domains [12]. ER-a36 possesses a unique 27
amino acid domain at the C-terminal that replaces the last 138
amino acids encoded by exons 7 and 8 of ER-a66 gene. Our
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tamoxifen could induce activation of the MAPK/ERK pathway
and stimulate cell proliferation through membrane-associated ER-
a36 [14]. We thus hypothesized that ER-a36 may be associated
with the agonist activity of tamoxifen. In the present report, we
studied the ER-a36 function in ER-positive MCF-7 breast cancer
cells and Hec1A endometrial cancer cells, and investigated the
contribution of the MAPK/ERK and PI3K/Akt pathways
mediated by ER-a36 to the agonist action of tamoxifen in
endometrial cancer.
Results
ER-a36 Is Expressed on the Plasma Membrane in MCF-7
and Hec1A Cells
ER-a3 6i san o v e lv a r i a n to fE R - a66 generated by alternative
promoter usage and alternative splicing [12]. To examine ER-
a36 expression in MCF-7 cells and Hec1A cells, Western blotting
analysis was performed using ER-a36 specific antibody against
the unique 20 amino acids at the C-terminal of ER-a36. ER-a36
i se x p r e s s e di nb o t hc e l ll i n e s( F ig. 1A, left). However, Western
blot analysis failed to detect ER-a66 expression in Hec1A cells
( F i g .1 A ,r i g h t ) ,c o n s i s t e n tw i t h that Hec1A is an ER-negative
cancer cell line [15]. To examine the cellular localization of
ER-a36, immunofluorescence assay was performed. In both cell
lines, immunofluorescence staining revealed an intense plasma
membrane distribution pattern (Fig. 1B). Caveolae are invagi-
nated microstructures on the plasma membrane in which
caveolin-1 serves as a scaffold protein to form the signaling
complex. As shown in Fig. 1C, caveolin-1 was primarily
expressed on the cell surface (red). Merged images of ER-a36
and caveolin-1 showed substantial co-localization signals (yellow)
on the plasma membrane.
Next, we analyzed ligand-induced ER-a36 expression. Hec1A
cell lines were treated with tamoxifen for different time points and
ER-a36 expression was assessed by Western blotting analysis,
revealing that ER-a36 expression was increased in tamoxifen
treated cells (Fig. 1D).
ER-a36 Mediates Estrogen- and Tamoxifen- Stimulated
ERK Activation
To probe the mechanism underlying the agonist effect of
t a m o x i f e ni ne n d o m e t r i a lc a n c er cells, we decided to examine
the function of ER-a36 in tamoxifen treated Hec1A cells. We
first examined the phosphorylation levels of MAPK/ERK, a
serine-threonine kinase involved in cell proliferation [16]. As
Figure 1. ER-a36 is expressed on the plasma membrane. A, The expression of ER-a36 and ER-a66 protein in MCF-7 and Hec1A cells. Protein
extracts were prepared from MCF-7 and Hec1A cells and used for Western blot analysis. B, The localization of ER-a36 in MCF-7 and Hec1A cells. Cells
cultured on coverslips were fixed and immunofluorescently stained with a specific anti-ER-a36 antibody (green). The cells were counterstained with
Hoechst 33258 (blue). C, The co-localization of ER-a36 and caveolin-1 on the plasma membrane of Hec1A cells. Green: ER-a36; Red: caveolin-1; blue:
nuclear; yellow, co-localization signals. Bar, 10 micrometers. D, Time-course analysis of ER-a36 expression in Hec1A cells. Hec1A cells were treated
with 2 mM Tam for indicated time points. Levels of protein expression were normalized with b-actin expression level, and each bar represents mean
value 6 SEM (n=3). *, P,0.05 compared to untreated cells.
doi:10.1371/journal.pone.0009013.g001
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in rapid phosphorylation of ERK1/2. Reprobing the mem-
brane with a total ERK1/2 antibody indicated that the total
ERK1/2 content was not changed, suggesting that the increased
ERK1/2 phosphorylation was not caused by increased ERK1/2
expression.
To test the involvement of ER-a36 in the activites of E2 and
tamoxifen observed in Hec1A cells that lack ER-a66 expression,
we decided to knock down ER-a36 expression with the siRNA
approach. We established stable cell lines that express shRNA
expression vector against ER-a36 (Hec1A/RNAi cells) and
examined ER-a36 expression (Fig. 2C and 2D). As shown in
Figure 2. ER-a36 mediates tamoxifen induced activation of the MAPK/ERK in Hec1A cells. A and B, Hec1A cells were treated with 10 nM
E2 or 2 mM Tam for the indicated time points. Levels of ERK1/2 phosphorylation were measured in protein extracts with Western blot analysis. Total
ERK1/2 was used as loading control. Each bar represents mean value 6 SEM (n=3). *, P,0.05 compared to untreated cells. C and D, ER-a36
expression in Hec1A/V and Hec1A/RNAi cells. Each bar represents mean value 6 SEM (n=3). *, P,0.05 compared to Hec1A/V cells. E, Hec1A/V and
Hec1A/RNAi cells treated with 10 nM E2 or 2 mM Tam were analyzed for the levels of ERK1/2 phosphorylation with Western blot. Total ERK1/2 was
used as loading control, and each bar represents mean value 6 SEM (n=3). *, P,0.05 compared to untreated cells (2) vs. treatments. F, Lysates from
Hec1A cells treated with DMSO (Lanes 1, 2 and 3), 10 nM E2 (Lanes 2 and 5), 2 mM Tam (Lanes 3 and 6) or pretreated with 10 mM U0126 (Lanes 4, 5
and 6) for 30 min were analyzed with Western blot analysis.
doi:10.1371/journal.pone.0009013.g002
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the ERK1/2 in Hec1A cells with ER-a36 knocked down,
suggesting that ER-a36 is the receptor that mediates the activities
of estrogen and tamoxifen.
Extracellular regulated kinase kinase (MEK) acts upstream of
ERK1/2 and could phosphorylate and activate ERK1/2 [17].
The MEK specific inhibitor U0126 effectively inhibited the
ERK1/2 activation stimulated by E2 and tamoxifen (Fig. 2F).
We also established stable cell lines from ER-positive MCF-7
breast cancer cells that constitutively express recombinant ER-a36
(MCF-7/ER36 cells) (Fig. 3A). In the control MCF-7 cells transfected
with the empty vector, E2 treatment induced phosphorylation of the
ERK1/2 (Fig. 3B), which could be abolished by tamoxifen (Fig. 3C).
However, tamoxifen induced phosphorylation of the ERK1/2 in
MCF-7/ER36 cells (Fig. 3D). MEK specific inhibitor U0126
effectively inhibited the ERK1/2 activation stimulated by E2 and
tamoxifen (Fig. 3E). Therefore, these results indicated that ER-a36
mediates the Ras/MEK/ERK pathway induced by both estrogen
and tamoxifen and suggested that ER-a36 may be involved in
tamoxifen resistance and even promote agonist action of tamoxifen.
ER-a36 Mediates Estrogen- and Tamoxifen-Stimulated
PI3K/Akt Activation
It is well known that the serine/threonine kinase Akt, or protein
kinase B, plays an important role in cell proliferation and survival
Figure 3. ER-a36 mediates E2 or tamoxifen induced activation of the MAPK/ERK in MCF-7 cells. A, Western blot analysis of ER-a36
expression in MCF-7/V and MCF-7/ER36 cells. Levels of expression were normalized to levels of b-actin, and each bar represents mean value 6 SEM
(n=3). *, P,0.05 compared to MCF-7/V cells. B and C, MCF-7/V cells treated with 10 nM E2 alone or with 2 mM Tam together for the indicated time
points. Protein extracts were analyzed with Western blot analysis. Total ERK1/2 was used as loading control. Each bar represents mean value 6 SEM
(n=3). *, P,0.05 compared to control cells. D, MCF-7/ER36 cells treated with 2 mM Tam for different time points were analyzed for ERK1/2
phosphorylation with Western blot. Levels of expression were normalized to levels of the total ERK1/2, and each bar represents mean value 6 SEM
(n=3).*, P,0.05 compared for untreated cells. E, Lysates were prepared from MCF-7/ER36 cells treated with DMSO (Lanes 1, 2 and 3), 10 nM E2 (Lanes
2 and 5), 2 mM of Tam (Lanes 3 and 6) or pretreated with 10 mM U0126 (Lanes 4, 5 and 6) for 30 min and immunoblotted with antibodies against
pERK1/2 or total ERK1/2.
doi:10.1371/journal.pone.0009013.g003
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treatment also induces activation of the Akt pathway in Hec1A
cells. Treatment of E2 and tamoxifen led to rapid phosphorylation
of Akt (Fig. 4A and 4B) whereas both E2 and tamoxifen failed to
induce the Akt phosphorylation in Hec1A/RNAi cells (Fig. 4C).
Tamoxifen also induced Akt phosphorylation in MCF-7 cells that
highly express recombinant ER-a36 (Fig. 4E). Pretreatment with
the PI3K inhibitor LY294002 abrogated the Akt phosphorylation
stimulated by E2 or tamoxifen in both cell lines (Fig. 4D and 4F),
indicating that ER-a36 mediates tamoxifen induced Akt phos-
phorylation through the PI3K pathway in these cells. Thus, our
data suggested that ER-a36-mediated activaton of the PI3K/Akt
pathway may also be involved in resistance and agonist action of
tamoxifen.
ER-a36 Is Involved in Regulation of c-Myc Protein
Expression in Hec1A Cells
Protooncogene c-Myc has profound mitogenic effects in cancer
cells through its ability to promote cell cycle progression [19].
Antisense oligonucleotides to c-Myc can inhibit breast cancer cells
proliferation [20]. Tamoxifen inhibits estrogen-induced c-Myc
expression in ER-a66-positive breast cancer cells. However, c-Myc
plays an important role in tamoxifen agonist action [21]. We
measured the expression levels of c-Myc in Hec1A cells treated
with E2 or tamoxifen. As shown in Fig. 5A, treatment with E2 or
tamoxifen induced c-Myc expression in Hec1A/V cells but not in
Hec1A/RNAi ER-a36 cells, which could be effectively abrogated
by the MEK inhibitor U0126 (Fig. 5B) and PI3K inhibitor
LY294002 (Fig. 5C).
ER-a36 Mediates Tamoxifen-Stimulated Cell Proliferation
in Hec1A Cells
To further study the role of ER-a36 in tamoxifen agonist
activity in endometrial cancer cells, Hec1A/V and Hec1A/RNAi
cells were treated with tamoxifen and their prolifaration was
measured with the MTT assay. MTT assay showed that tamoxifen
stimulated growth of Hec1A/V cells. However, tamoxifen was
able to inhibit the growth of Hec1A/RNAi cells in a dose-
dependent fashion (Fig. 6A). The cell proliferation induced by
tamoxifen was inhibited by the MEK inhibitor U0126 and PI3K
inhibitor LY294002 (Fig. 6B), suggesting that both the MAPK/
ERK and PI3K/Akt pathways were involved in E2 and tamoxifen
stimulated cell growth in endometrial cancer cells.
We observed that tamoxifen strongly inhibited cell proliferation
in the MCF-7/V cells, consistent with previous reports that
tamoxifen functions as a potent antagonist in ER-positive breast
cancer MCF-7 cells [22]. However, MCF-7/ER36 cells that
constitutively express high levels of recombinant ER-a36 exhibited
insensitivity to tamoxifen treatment (Fig. 6C). The MEK inhibitor
U0126 and PI3K inhibitor LY294002 furthermore inhibited
growth of both cell lines (Fig. 6D). These results again suggest that
high level of ER-a36 expression may confer resistance to tamoxifen.
Discussion
Tamoxifen is a SERM that has been widely used to treat
advanced ER-positive breast cancer and to prevent breast cancer
in high risk pre- and post-menopausal women as a chemopreven-
tive agent [23,24]. However, tamoxifen also has partial estrogenic
activity in the uterus that can lead to endometrial hyperplasia [25].
Long-term tamoxifen usage is associated with an increased
incidence of endometrial cancer [26]. Here we reported that a
novel variant of ER-a, ER-a36, that is highly expressed on the
plasma membrane of Hec1A endometrial cancer cells and in the
endometrial cancer specimens from patients who had been treated
with tamoxifen for at least three years. Both E2 and tamoxifen
induced cell proliferation of Hec1A cells presumably through the
ER-a36 mediated non-genomic signaling pathways.
A number of hypotheses have been postulated to explain
tamoxifen’s agonist action in endometrial carcinogenesis. It has
been suggested that reactive metabolites of tamoxifen form DNA-
adducts and generate mutagenicity in the endometrial tissue [27].
It has also been demonstrated that the AF1 domain of ER-a66 as
well as cell- and promoter-specific coactivator recruitment are
involved in the tamoxifen agonist action [28,29]. The role of
tamoxifen in endometrial carcinogenesis may utilize distinct
genomic activity [30]. Recently, accumulating evidence suggested
that membrane-initiated signaling pathways confer tamoxifen
resistance and agonist action through different kinase cascades and
distinct second messengers [15].
The MAPK family consists of ERK, JNK and P38. ERK plays
an essential role in cell growth and proliferation. JNK and P38 are
involved in cell differentiation and apoptosis induced by stress
stimuli such as UV light [31], c radiation [32,33], DNA-damaging
and chemopreventive drugs [34]. Many oncogenic signaling
molecules activate the MAPK/ERK pathway [35]. ERK
expression is usually increased and its activity is up-regulated in
breast cancer tissues compared to neighboring normal tissues [36].
Furthermore, tamoxifen resistance in vivo is predominantly
mediated by non-genomic mechanisms. Genomic estrogen action
seems less active [37,38]. In this study, we found that ER-a36
mediates both E2- and tamoxifen-induced activation of the
MAPK/ERK pathway and ER-a36 overexpression in tamoxifen
sensitive MCF-7 cells reduced sensitivity to tamoxifen. In addition,
ER-a36 mediates tamoxifen induced activation of the MAPK/
ERK pathway and also contributes to agonist action of tamoxifen
in Hec1A endometrial cancer cells. Endometrial cancer tissues
that highly express ER-a36 also displayed high levels of the ERK
phosphorylation.
The PI3K/Akt pathway plays an important role in cell growth
and survival [39]. Akt is activated by many signaling pathways,
such as overexpression of growth factor receptors, [40]. Introduc-
tion of a constitutively active Akt into MCF-7 cells could induce
tamoxifen resistance by protecting cells from tamoxifen-induced
apoptosis [41]. In addition, the Akt activity is dramaticaly
increased in tamoxifen- resistant MCF7 cells [18]. In phosphor-
ylated Akt-positive patients, endocrine therapy has worse efficacy
than in phosphorylated Akt-negative patients [42]. In this study,
we found ER-a36 mediated tamoxifen-stimulated activation of
Akt in cells with high levels of ER-a36 expression suggesting that
the activation of the PI3K/Akt pathway mediated by ER-a36
contributes to the resistance and agonist action of tamoxifen.
The c-Myc protein is a nuclear transcription factor that plays an
essential role in cell growth [43]. Previous studies have
demonstrated that MAPK/ERK and PI3K/Akt pathways regu-
late c-Myc protein expression [44,45,46]. We found both E2 and
tamoxifen induced c-Myc expression through ER-a36-mediated
activation of ERK and Akt. Incubation of Hec1A cells with MEK
inhibitor U0126 and PI3K inhibitor LY294002 blocked E2- and
tamoxifen- induced c-Myc expression. Therefore, tamoxifen exerts
agonist action through ER-a36-mediated non-genomic pathway.
In summary, we report here that ER-a36 is expressed on the
plasma membrane and in the cytoplasm of endometrial carcinoma
cells. We further demonstrated that both E2 and tamoxifen
promoted proliferation of endometrial cancer cells through ER-
a36-mediated activation of the MAPK/ERK and PI3K/Akt
pathways and ER-a36 overexpression led to tamoxifen resistance
in MCF-7 cells. Our results provide important novel information
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PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9013Figure 4. ER-a36 mediates E2 and tamoxifen induced activation of Akt. Hec1A cells were treated with 10 nM E2 (A) or 2 mM Tam (B) for the
indicated time points and the lysates were immunoblotted with an antibody against phosphorylated Akt. Levels of phosphorylation were normalized
with the total Akt protein, and each bar represents mean value 6 SEM (n=3). *, P,0.05 compared to untreated cells. C, Western blot analysis of the
Akt phosphorylation in Hec1A/V and Hec1A/RNAi ER36 cells treated with 10 nM E2 or 2 mM Tam for 10 min. Levels of phosphorylation were
normalized with the total Akt protein, and each bar represents mean value 6 SEM (n=3). *, P,0.05 compared to untreated cells. #,P ,0.05
compared with E2- or Tam-treated Hec1A/V cells. D, Hec1A cells pretreated with 50 mM PI3K inhibitor LY294002 (LY, Lanes 4, 5 and 6) for 2 h and then
treated with 10 nM E2 (Lanes 2 and 5) or 2 mM Tam (Lanes 3 and 6) for 10 min. E, Western blot analysis of Akt phosphorylation in MCF-7/ER36 cells
treated with 2 mM Tam for the indicated time points. Expression was normalized to total Akt, and each bar represents mean value 6 SEM (n=3).
*, P,0.05 compared for untreated cells. F, Lysates were prepared from MCF-7/ER36 cells treated with DMSO (Lanes 1 and 2), 2 mM of Tam (Lanes 2
and 4) or pretreated with 50 mM PI3K inhibitor LY294002 (LY, Lanes 3 and 4) for 2 h, and immunoblotted with antibodies against phosphorylated Akt
or total Akt.
doi:10.1371/journal.pone.0009013.g004
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PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9013Figure 5. ER-a36 mediates E2 and tamoxifen induced c-Myc expression. A, Western blot analysis of c-Myc expression in Hec1A/V and
Hec1A/RNAi cells treated with 10 nM E2 or 2 mM Tam for 12 h. Levels of expression were normalized to the levels of b-actin, and each bar represents
mean value 6 SEM (n=3). *, P,0.05 compared to untreated cells (2) vs. treatments. #,P ,0.05 compared to Tam-treated Hec1A/V cells. B and C,
Hec1A cells were treated for 12 h with 10 nM E2 or 2 mM Tam or together with 10 mM of MEK inhibitor U0126 or 50 mM PI3K inhibitor LY294002.
Levels of c-Myc expression were normalized to the levels of b-actin, and each bar represents mean value 6 SEM (n=3). *, P,0.05 compared to
untreated cells (2) vs. treatments. #,P ,0.05 compared to E2- and Tam-treated Hec1A/V cells.
doi:10.1371/journal.pone.0009013.g005
Figure 6. ER-a36 mediates tamoxifen stimulated growth in MCF-7 and Hec1A cells. A, Hec1A cells transfected with the empty expression
vector (Hec1A/V) or Hec1A cell lines in which ERa36 had been stably knocked down by shRNA expression (Hec1A/RNAi) were plated 96-well plates
(3610
3 cells/well). The cells were treated with different concentrations of Tam in medium containing 2.5% dextran charcoal-stripped FBS for 72 h.
MTT assay was performed as described in materials and methods. Results of three independent experiments were averaged and mean value 6 SEM
are shown. *, P,0.05 compared to Tam-treated Hec1A/V cells respectively. B, Hec1A cells were treated with 10 nM E2 or 2 mM Tam together with
10 mM of the MEK inhibitor U0126 or 50 mM PI3K inhibitor LY294002 respectively for 72 h, and analyzed by MTT assay. Results of three independent
experiments were averaged and mean value 6 SEM are shown. *, P,0.05 compared to control cells. C, Empty expression vector transfected MCF-7
cells (MCF-7/V) or MCF-7 cells transfected with ERa36 expression vector (MCF-7/ER36 cells) were plated in 96-well plates (5610
3 cells/well). The cells
were treated with different concentrations of tamoxifen in medium containing 10% FBS for 72 h. MTT assay was performed. Results of three
independent experiments were averaged and mean value 6 SEM are shown. *, P,0.05 compared to Tam-treated MCF-7/ER36 cells respectively. D,
MCF-7/V and MCF-7/ER36 cells were treated with 2 mM Tam together with 10 mM U0126 or 50 mM PI3K inhibitor LY294002 respectively for 72 h and
analyzed by MTT assay. Results of three independent experiments were averaged and mean value 6 SEM are shown. *, P,0.05 compared to control
MCF-7/V cells.
doi:10.1371/journal.pone.0009013.g006
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agonist action of tamoxifen.
Materials and Methods
Materials and Reagents
All chemicals and reagents were purchased from Sigma unless
otherwise indicated. Polyclonal anti-ERK1/2 antibody, polyclonal
anti-phospho-ERK1/2 antibody (Thr
202/Tyr
204), polyclonal anti-
caveolin-1 -TRITC antibody, monoclonal anti-c-Myc antibody,
polyclonal anti-Akt antibody, monoclonal anti-ER-a66 (D-12)
antibody and monoclonal anti-b-actin antibody were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal anti-
phospho-Akt (Ser
473) antibody was obtained from Signalway
Antibody (Pearland, TX). The ER-a36 specific antibody against
the 20 unique amino acids at the C-terminal of ER-a36, ER-a36
expression plasmid, ER-a36 shRNA expression vector and the
empty expression vector were described before [12,14]. U0126
was purchased from Calbiochem (La Jolla, CA).
Cell Culture and Cell Lines
MCF-7 human breast cancer cells were obtained from ATCC
(Manassas, VA), and human Hec1A endometrial cancer cells were
obtained from Dr. Li-Hui Wei (Peking University People’s
Hospital, Beijing). Both cell lines were maintained at 37uC with
5% CO2 in appropriate culture medium. To establish MCF-7 cells
expressing recombinant ER-a36, cells were plated at a density of
1610
5 cells per 60-mm dish and transfected 24 hours later with an
expression vector driven by the cytomagalovirus (CMV) promoter
in the mammalian expression vector pCB6+ as described
elsewhere [14], using the Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). The expression vector contains the full-length
ER-a36 cDNA. The empty expression vector was also transfected
into cells to serve as a control. Forty-eight hours after transfection,
the cells were re-plated and selected with 500 mg/ml of G418 for
two weeks. The medium was changed every three days until
colonies appeared. Clones were expanded for further analysis.
Clones with high ER-a36 expression were a mixture of more then
twenty clones and termed MCF-7/ER-a36. A cell line with pooled
clones transfected with the empty expression vector was named
MCF-7/V and used as a control.
We also established cell lines from Hec1A cells transfected with
an ER-a36 shRNA expression vector (Hec1A/RNAi) and the
empty expression vector (Hec1A/V). Briefly, ER-a36 shRNA
expression vector pRNAT-U6.1/Neo plasmid containing the
shRNA against ER-a36 (GenScript Corp. TX) and the empty
expression vector were transfected into Hec1A cells with
Lipofectamine 2000 according to the manufacturer’s instruction.
Forty-eight hours after transfection, the cells were re-plated and
selected with G418 (600 mg/ml) for two weeks. Clones were
expanded for further analysis.
Immunofluorescence and Confocal Microscopy
The cellular localization of protein was determined by indirect
immunofluorescence. Hec1A or MCF-7 cells cultured on sterile
glass coverslips were fixed in 4% paraformaldehyde in PBS for
10 min. After being permeabilized with 0.4% Triton X-100 at
room temperature for 10 min, cells were blocked in 4% BSA-
supplemented PBS for 1 h and incubated overnight at 4uC with
anti-ER-a36-specific antibody. After three washes in PBS, the cells
were labeled with FITC-conjugated secondary antibody. The
DNA dye Hoechst 33258 was used for nuclear staining.
For double staining of ER-a36 and caveolin-1, after ER-a36
staining and wash in PBS, the cells were blocked in 4% BSA-
supplemented PBS for 1 h at room temperature. After incubation
with anti-caveolin-1-TRITC antibody overnight, the cells were
further washed in PBS and stained with Hoechst 33258.
Microscopic analyses were performed using a Confocal Laser-
Scanning Microscope (Zeiss LSM 510 META, Germany).
Semi-Quantitative RT-PCR
Total RNA was extracted by TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruction. Total
RNA (1.6 mg) was used for production of the first strand cDNA by
reverse transcriptase (Takara, Dalian, P.R.China). The following
primer sets were designed for the amplification of human ER-a36
(BX640939, 1145–1434 bp): forward, 59-CAAGTGGTTTCCT-
CGTGTCTAAAGC-39 and reverse, 59-TGTTGAGTGTTGG-
TTGC CAGG-39; Human GAPDH mRNA was amplified by the
forward primer 59-ACGGATTTGG TCGTATTGGG-39 and the
reverse primer 59-TGATTTTGGAGGGATCTCGC-39.
MTT Assay
Cell proliferation was analyzed using the 3-(4,5-dimethylthiazol-
2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay [47]. Briefly,
cells were seeded in 96-well plates to a final concentration of
5610
3/well for MCF-7/V and MCF-7/ER36 cells or 3610
3/well
for Hec1A/V and Hec1A/RNAi cells. MCF-7/V and MCF-7/
ER36 cells were incubated in DMEM medium containing 10%
FCS with the indicated treatments. Hec1A/V and Hec1A/RNAi
cells were incubated in phenol-red free medium containing 2.5%
dextran charcoal-stripped FCS (Biochrom AG, Berlin, Germany)
with the indicated treatments. The cells were then incubated with
MTT (0.5 mg/ml) for 4 h at 37uC. After removal the medium
containing the MTT reagent, 150 ml of DMSO were added to
each well. The plates were read at wavelength of 490 nm using a
microplate reader (Bioteck Powerwave
TM, USA).
Western Blotting Analysis
Cells were grown in phenol-red-free medium with 2.5% dextran
charcoal- stripped FCS for 48–72 hours and then switched to
medium without serum 12 h before stimulation by the agents
indicated. The cells were collected in ice-cold PBS, and the cell
extracts were prepared in RIPA buffer with the proteinase inhibitor
cocktail from Sigma (St. Louis, MO). Cell lysates were boiled with
gel-loading bufferfor 5 min at 100uC, resolved on 10%SDS-PAGE,
transferred to PVDF membranes, probed with appropriate
antibodies and visualized with enhanced chemiluminescence (ECL)
detection reagents (Amersham Pharmacia Biotech., Piscataway, NJ).
Statistical Analysis
Statistical analysis was performed using paired-samples t-test, or
ANOVA followed by the Student-Newman-Keuls testing to
determine differences in means. P,0.05 was considered statisti-
cally significant.
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